CD39 une nouvelle cible thérapeutique pour l'immunothérapie des cancers Nathalie Bonnefoy

CD39 une nouvelle cible thérapeutique pour
l'immunothérapie des cancers
Nathalie Bonnefoy
9ième Journées Scientifiques Cancéropôle Nord-Ouest – 18 Mai 2016

• Increased proliferative capacity
• Resistance to cell death
• Increased invasion and metastasis
• Etc…..
• Source of neo-antigens
• Release of chemokines & cytokines
Cancer stem cell
Cancer cell
Tumor associated
fibroblasts
Cross-talk between tumor cells and the microenvironment
Tumor: a complex architecture
P53 Bcl-2
Ras
Etc…
APC
Tumor infiltrating lymphocytes
Effector T cells
NK cells
Tregs…
Immune myeloid cells
Macrophages
MDSC
DC…

Cancer stem cell
Cancer cell
Cross-talk between tumor cells and the microenvironment
Tumor: a complex architecture
Tumor infiltrating lymphocytes
Effector T cells
NK cells
Tregs…
Immune myeloid cells
Macrophages
MDSC
DC…
Pro-tumoral effect
Anti-tumoral effect
Tumor associated
fibroblasts

Cancer stem cell
Cancer cell
Tumor associated
fibroblasts
Cross-talk between tumor cells and the microenvironment
Tumor: a complex architecture
Tumor infiltrating lymphocytes
Effector T cells
NK cells
Tregs…
Immune myeloid cells
Macrophages
MDSC
DC…

Hallmarks of cancer in 2011
Anti-tumor immunity:
a barrier to tumor formation & progression
Three first FDA approved immune checkpoint inhibitors for melanoma
Ipilimumab (2011), Nivolumab (2014) and Pembrolizumab (2014)
Manipulation of the immune system
to reinforce anti-tumor immunity
Tumor specific T cell
Tumor cell